It’s cheap, easy to make and in demand overseas. So why can’t this Texas-born COVID-19 vaccine break into the U.S. market?

It’s cheap, easy to make and in demand overseas. So why can’t this Texas-born COVID-19 vaccine break into the U.S. market?

A Houston vaccine team would like a U.S. distributor but for now focuses its efforts abroad to inoculate those in countries where COVID-19 variants surface more quickly. BY KAREN BROOKS HARPER The day before COVID-19 claimed its first Texas victim in 2020, Dr. Peter...

read more
Potential Clinical Benefits of Quercetin in the Early Stage of COVID-19: Results of a Second, Pilot, Randomized, Controlled and Open-Label Clinical Trial

Potential Clinical Benefits of Quercetin in the Early Stage of COVID-19: Results of a Second, Pilot, Randomized, Controlled and Open-Label Clinical Trial

By Di Pierro F, et al. Published June 24, 2021 in the International Journal of General Medicine Abstract Background The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of the ongoing global pandemic known as COVID-19. Based on the potential...

read more